

Medication use and practice in North East and North Cumbria analysis and action

Dr Neil O'Brien

Executive Medical Director

Medicines in NENC

- Primary care spend approx. £600m/year (approximately 10% of all ICB spend)
 - Over 7 million prescriptions/month
 - 630+ pharmacies, and dispensing practices
- Secondary care spend £400-500m/year
- Volatile budget, and closely linked to supply chain challenges

How do we manage prescribing as a system

Formulary, guidance and governance

- Making good decisions about which medicines can and should be used in which circumstances
- Restricting access to medicines which are not evidence based or cost effective
- Benchmarking/data

Changing behaviour

- Incentives
- Behavioural insights, communications – public and prescriber facing

Improving systems

- Medicines
 Optimisation
 pharmacists in
 practices/PCNs
- Software to aid decisions
- Eliminating systemic drivers of waste and poor quality of care

Prevention and nonpharmacological

- Preventing long term ill health and the consequent resource utilisation of that
- Promoting nonpharmacological options where these are evidence based



Prescribing

- Higher spend than England average on medicines
- Closely linked to deprivation and highly reflective of demographics
- NENC is low on cost per item, but high on prescribing volume – overprescribing

Weighted per capita prescribing costs

Greater Manchester		29.77
West Yorkshire		29.15
South Yorkshire		29.04
North East and North Cumbria		28.81
North East and Yorkshire		28.66
North of England		28.60
North West		28.52
Cheshire and Merseyside		28.19
Humber and North Yorkshire	· · · · · · · · · · · · · · · · · · ·	27.52
Lancashire and South Cumbria		27.09
England		26.76

Weighted per capita prescribing frequencies

North East and North Cumbria	1.12
South Yorkshire	1.10
North East and Yorkshire	1.04
North of England	1.01
Greater Manchester	1.00
North West	0.97
West Yorkshire	0.96
Cheshire and Merseyside	0.96
Humber and North Yorkshire	 0.94
Lancashire and South Cumbria	0.94
England	0.87

National Medicines Optimisation Opportunities

NHSE produced a list of 16 areas for systems to choose from

These are a mix of financial, quality and safety measures

NENC have prioritised:

- Addressing problematic polypharmacy/overprescribing
- Improving valproate safety
- Reducing opioid use in non-cancer pain
- Appropriate use of blood glucose meters and testing strips
- Obtaining secondary care medicines in line with framework agreements

Overprescribing

10% of medicines prescribed in primary care are 'pointless'. Addressing this would lead to:





REDUCTION IN HOSPITAL ADMISSIONS



REDUCTION IN ADVERSE INCIDENTS – BETTER OUTCOMES



REDUCTION IN CARBON FOOTPRINT



£30M/YEAR REDUCTION IN WASTE



REDUCTION IN HEALTH INEQUALITIES



REDUCTION IN
DISPROPORTIONATE
PRESCRIBING BURDEN
ON BAME, DEPRIVED
AND LD COMMUNITIES



GREATER PRIMARY CARE CAPACITY – 400,000 HOURS/MONTH



HAPPIER AND HEALTHIER PATIENTS


Overprescribing

- Prescribing can act as a pressure valve
 - Long secondary care waiting lists e.g. surgery
 - Lack of non-pharmacological alternatives e.g. counselling
 - General practice pressures limited time for medicines reviews
 - Virtual appointments antibiotic prescribing in covid
 - Private providers people accessing healthcare in other ways not limited by local guidelines
 - Poor health literacy



Polypharmacy

% patients taking > 10 medicines



Overprescribing strategy



Evidence based systems and deployment of resources



Medicines supply



Double the supply problems there were in 2022 - affects about 10% of prescribed medicines at any one time



Causes include covid, geopolitics, fuel prices, Brexit, changes in taxes on medicines and increased demand



Notable recent examples include HRT, ADHD, antidepressants, diabetes and obesity medicines



Managing shortages demands significant resources from the system and impact on patient care

Medicines supply

Over the last 12 months we estimate that price concessions have cost NHS North East and North Cumbria Integrated Care Board an additional £15,637,000 (of which £10,167,000 is in the current financial year)



Cost concessions – temporary higher prices for medicines in short supply cost the ICB over £15m last year

Medicines Safety



Opioids – a case study





- Number of patients on high dose opioids has reduced from 8,256 in 2018 to 3,804 last month (a 54% reduction)
- NENC has moved from highest prescriber of opioids in England to 78th centile
- Huge cultural shift required with significant investment in time and energy

Shared care



- Prescribing of medicines in primary care where secondary care retain some clinical responsibility
- Challenging because of increasing workload in primary care along with waiting lists in secondary care
- Not core contract work for general practice, but essential to ensure secondary care remains able to see new patients

Preventative prescribing

- Increasing evidence for, and use of, medicines for prevention
 - Include anticoagulants, lipid control, diabetes
- Represents a short-term challenge to resources, for longer term outcome improvements
- Balance between using new technologies versus promoting non-pharmacological approaches

Research and innovation



Engagement with the pharmaceutical and medical technology industries has significant potential to improve quality of care and drive investment in NENC



Needs to be appropriate engagement at a system level to ensure adequate governance



ICB/Industry forum in development (supported by Health Innovation North East and North Cumbria)

Medicines Optimisation strategy



In development, and reflects change in resource available to the team post ICB 2.0



System wide approach to improving the effectiveness, safety, quality and efficiency of medicines use



Will engage patients, prescribers and all parts of the system



Will be informed by behavioural insights work

Medicines



Questions?